Anita Fletcher, MD | Appointed by NKGen as National Principal Investigator for Phase 2a Troculeucel Trial

NKGen Biotech, Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator (“PI”) for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer’s disease (NCT06189963). In addition to Dr. Fletcher’s appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orlando will be the first clinical site on the East Coast with the intent of enrolling moderate stage Alzheimer’s Disease (“AD”) patients in the very near term.

Read more about the announcement and the study by clicking the button below.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News

Alcohol, Marijuana and Type 1 Diabetes:

Whether it's a backyard barbecue, a football game or dinner with friends, alcohol and marijuana are common parts of social life. For people with Type 1 diabetes (T1D), understanding how they affect...

News

The Science That Moves Medicine Forward:

Have you ever wondered how breakthrough medicines are developed, how doctors determine the most effective treatments, or how healthcare continues to advance? The answer lies in clinical research—the...

News

Advancing Cancer Research Closer to Home

At AdventHealth, we believe research is not separate from care. We believe the advancements made are what allow us to help our patients feel whole. That commitment is reflected in a new collaboration...

News

Moving More, Managing Better

For people living with type 1 diabetes, managing blood sugar is rarely simple. It’s a daily balancing act involving insulin, food, physical activity, technology and a constant stream of decisions.